For years, rheumatologists would rather fight to stay on a TNF inhibitor (TNFi) than switch to a non-TNFi biologic when rheumatoid arthritis (RA) therapy fails. A new prescriber analysis shows that after the first TNFi failure, a second TNFi is still preferred over swapping to a non‐TNFi, even though there was greater time on drug with a non‐TNFi biologic. 

The largest study, to date, shows that in‐hospital mortality of systemic lupus erythematosus (SLE) patients has significantly improved between 2006 and 2016, with a high mortality burden among U.S. Blacks and Hispanics with lupus.

I attended the #whitecoats4blacklives rally at Dallas City Hall a few weeks ago to support our black colleagues, patients, and friends. It was inspiring, humbling, and emotional. I encouraged other physicians to join me, posting on the Dallas Physician Facebook page that we need to lead by example for our community and our children to fight structural racism. One black physician posed a very important point to my post, “What permanent

With a global pandemic, protests, fake news, real news, politics, home schooling, quarantine, and constant change to our day to day lives looming, the time to reprioritize is now. We need to step up for our patients, staff, loved ones, and ourselves. This week, I challenge you to reconsider how your mental health affects not only your life, but those of everyone around you.

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.